Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310

Trial Profile

Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Treprostinil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 06 Dec 2023 Results of three additional years of open-label observation after the close of the placebo-controlled, event-driven study, associated with improved survival in FREEDOM-EV and its Open-Label Extension published in the Advances in Therapy
    • 19 Oct 2022 Results assessing efficacy of treprostinil in pulmonary arterial hypertension participants in Freedom-Ev (NCT01560624) and the Freedom-Ev Open-Label Extension (OLE, NCT01560637) studies, presented at the CHEST Annual Meeting 2022 by Annual Meeting of the American College of Chest Physicians.
    • 14 Oct 2022 According to a United Therapeutics Corporation media release, long-term data from this trial will be presented at the CHEST 2022 Annual Meeting hosted by the American College of Chest Physicians.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top